ES2353761T3 - Formulaciones que contienen salicilatos y su uso para tratar la enfermedad inflamatoria intestinal. - Google Patents

Formulaciones que contienen salicilatos y su uso para tratar la enfermedad inflamatoria intestinal. Download PDF

Info

Publication number
ES2353761T3
ES2353761T3 ES04769427T ES04769427T ES2353761T3 ES 2353761 T3 ES2353761 T3 ES 2353761T3 ES 04769427 T ES04769427 T ES 04769427T ES 04769427 T ES04769427 T ES 04769427T ES 2353761 T3 ES2353761 T3 ES 2353761T3
Authority
ES
Spain
Prior art keywords
release
acid
azo
bis
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04769427T
Other languages
English (en)
Spanish (es)
Inventor
John Devane
Jackie Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGI Therapeutics Research Ltd
Original Assignee
AGI Therapeutics Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AGI Therapeutics Research Ltd filed Critical AGI Therapeutics Research Ltd
Application granted granted Critical
Publication of ES2353761T3 publication Critical patent/ES2353761T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES04769427T 2003-09-03 2004-09-02 Formulaciones que contienen salicilatos y su uso para tratar la enfermedad inflamatoria intestinal. Expired - Lifetime ES2353761T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49936503P 2003-09-03 2003-09-03
US499365P 2003-09-03

Publications (1)

Publication Number Publication Date
ES2353761T3 true ES2353761T3 (es) 2011-03-04

Family

ID=34272809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04769427T Expired - Lifetime ES2353761T3 (es) 2003-09-03 2004-09-02 Formulaciones que contienen salicilatos y su uso para tratar la enfermedad inflamatoria intestinal.

Country Status (13)

Country Link
US (2) US7737133B2 (enExample)
EP (1) EP1663253B1 (enExample)
JP (1) JP5108304B2 (enExample)
AT (1) ATE489956T1 (enExample)
AU (1) AU2004267953A1 (enExample)
CA (1) CA2535923A1 (enExample)
DE (1) DE602004030353D1 (enExample)
ES (1) ES2353761T3 (enExample)
IL (1) IL173684A0 (enExample)
MX (1) MXPA06002048A (enExample)
NO (1) NO20061489L (enExample)
WO (1) WO2005021009A2 (enExample)
ZA (1) ZA200601356B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP2361620B1 (en) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
NZ603744A (en) * 2005-08-24 2014-06-27 Salix Pharmaceuticals Inc Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2050439B1 (en) * 2006-08-11 2016-11-23 Asahi Kasei Kabushiki Kaisha Process for production of spherical granule containing slightly water-soluble substance
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
MX2009001711A (es) 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Formulaciones de liberacion sostenida de topiramato.
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
GB2461822B (en) * 2007-03-20 2011-09-21 Isp Investments Inc Meltable binder for melt granulation and/or pelletization
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
JP2011500553A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20120093939A1 (en) * 2008-12-17 2012-04-19 Altheus Therapeutics, Inc. Oral formulations
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
US8748472B2 (en) 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
US8597683B2 (en) * 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
JP5897196B1 (ja) * 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
CA3086767A1 (en) * 2018-01-03 2019-07-11 Ferring B.V. Oral liquid pharmaceutical compositions of aminosalicylates
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN112569915B (zh) * 2020-12-27 2023-06-23 王晓玉 一种煤矿井水除铀吸附剂、及其制备方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (enExample) * 1980-03-20 1982-03-11
SE8002322L (sv) * 1980-03-26 1981-09-27 Pharmacia Ab Medel for behandling av inflammatoriska tarmsjukdomar
US4374932A (en) * 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8303399D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran
SE8303400D0 (sv) 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicylsyra och salt derav samt deras farmaceutiska beredning och anvendning
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4705515A (en) * 1984-10-26 1987-11-10 Alza Corporation Dosage form for administering drug of the colon
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
SE9002339L (sv) 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
FR2692484B1 (fr) 1992-06-22 1995-06-30 Gouchet Franck Nouvelle forme galenique de 4-asa a liberation controlee.
WO1995016451A1 (fr) 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
JPH072650A (ja) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
ATE357221T1 (de) * 1994-04-22 2007-04-15 Astellas Pharma Inc Kolon-spezifisches arzneistofffreisetzungssystem
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
JPH0840941A (ja) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2000103732A (ja) * 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd 腸内適所放出型製剤
KR100695562B1 (ko) 1998-09-28 2007-03-15 워너-램버트 캄파니 엘엘씨 Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE59905248D1 (de) * 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
AU2001279064A1 (en) * 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
HU229291B1 (en) * 2001-01-31 2013-10-28 Evonik Roehm Gmbh Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease

Also Published As

Publication number Publication date
AU2004267953A1 (en) 2005-03-10
IL173684A0 (en) 2006-07-05
CA2535923A1 (en) 2005-03-10
ATE489956T1 (de) 2010-12-15
US20100278917A1 (en) 2010-11-04
US7928092B2 (en) 2011-04-19
NO20061489L (no) 2006-05-30
ZA200601356B (en) 2007-07-25
WO2005021009A2 (en) 2005-03-10
US20050090473A1 (en) 2005-04-28
EP1663253B1 (en) 2010-12-01
US7737133B2 (en) 2010-06-15
WO2005021009A3 (en) 2005-07-14
EP1663253A2 (en) 2006-06-07
JP2007504212A (ja) 2007-03-01
DE602004030353D1 (de) 2011-01-13
JP5108304B2 (ja) 2012-12-26
MXPA06002048A (es) 2006-05-25

Similar Documents

Publication Publication Date Title
ES2353761T3 (es) Formulaciones que contienen salicilatos y su uso para tratar la enfermedad inflamatoria intestinal.
ES2739856T3 (es) Formulaciones de liberación modificada y procedimientos para el tratamiento de la enfermedad intestinal inflamatoria
ES2545589T3 (es) Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico
ES2550035T3 (es) Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
ES2409347T3 (es) Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
ES2739888T3 (es) Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación
JP2019514873A (ja) 徐放性懸濁組成物
JPH01502589A (ja) 味がマスクされた医薬組成物
JP2017536404A (ja) 胃保持性の徐放性懸濁組成物
ES2560240T3 (es) Sistema de suministro pulsátil controlado por pH, métodos para la preparación y uso del mismo
ES2374158T3 (es) Preparación farmacéutica para la administración oral con liberación controlada de principio activo en el intestino delgado y procedimiento para su preparación.
ES2303314T3 (es) Formulaciones de liberacion prolongada de dipiridamol y procedimiento para su preparacion.
BRPI0615014A2 (pt) composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma
US20060280788A1 (en) Delivery and formulations of mast cell stabilizers
WO2002066004A1 (fr) Compositions a liberation controlee de medicament
US20090062242A1 (en) Methods and compositions for treating gastrointestinal conditions
Thakur Gastroretentive Drug Delivery System (GRDDS): A Novel Approach to Improve Therapeutic Efficacy
HU227881B1 (en) Sustained release pharmaceutical preparation containing carvedilol
TR201615312A1 (tr) Antiviral Farmasötik Terkipler